CIP2A is a target of bortezomib in human triple negative breast cancer cells

Breast Cancer Research, 04/30/2012

Cancerous inhibitor of protein phosphatase 2A (CIP2A) is a major determinant mediating bortezomib–induced apoptosis in triple negative breast cancer (TNBC) cells. CIP2A may thus be a potential therapeutic target in TNBC.

Print Article Summary Cat 2 CME Report